The hexarelin route-comparison paper reports growth-hormone responses. Reading those responses as direct measurements of the amount of hexarelin in circulation would change what the experiment measured. Primary paper
Study snapshot
The investigators studied 12 healthy young volunteers using several administration routes and reference treatments. They reported route- and exposure-condition-related GH responses, including areas under the GH response curve. The abstract also reports estimates termed biological bioavailability. Its central evidence concerns stimulation of hormone release, not long-term functional improvement. Primary paper
Our interpretation: label the substance on the graph
An area under a curve needs both axes identified. Is the vertical axis the administered compound, a hormone released in response, or a downstream marker? Those curves may answer different questions even when all are summarized as an AUC.
In a hypothetical experiment, two exposure conditions could produce similar hormone responses while producing different circulating drug concentrations. Alternatively, similar drug concentrations could lead to different responses in different people. This is why pharmacodynamic response and direct pharmacokinetic exposure should not be silently substituted for one another.
Comparing routes requires more than a ranking
Our full-text appraisal would inspect how the authors derived their biological-availability estimates, what normalization they used, the sampling schedule, and how repeat measurements were handled. The exact administered material and experimental conditions must remain attached to any comparison.
A route ranking is not a personal administration recommendation. Formulation, studied conditions, and safety information would all matter to a clinical decision. This record therefore does not convert the experimental conditions into a self-use schedule or a claim that an untested preparation will behave identically.
Frequently asked questions
Is this the same paper as PMID 7957536?
No. This is the distinct multi-route report indexed as PMID 8126144.
What response was emphasized?
Growth-hormone release under the study conditions.
Was the GH AUC a hexarelin concentration AUC?
No. The reported hormone-response curve must keep its own label.
Does biological availability always mean directly measured absorption?
Not necessarily. The study's operational definition and derivation must be checked.
Did a hormone response establish muscle or recovery benefits?
Those are separate outcomes and are not established by the response alone.
Can the experimental routes be treated as interchangeable?
Not without evidence matched to the material and intended claim.
What remains before release?
Full-methods verification of the availability calculations and review of publication history and overlap with the existing physiology page.